RFP QuestBeta
ClosedStage · preprocurement

NHS England

Prior Information Notice - Licence Variation for Anastrozole

Medical Equipment & PharmaCPV 33600000
ValueValue not published
Deadline24 Sept 2021
Published7 Sept 2021
RegionLondon
Timeline
Published 7 Sept 2021ClosedCloses 24 Sept 2021
Match for your company
Sign up free to see how well this tender matches your company — the score, the signals that align, and where the gaps are.
The brief

The Medicines Repurposing Programme has been established by NHS England and NHS Improvement (NHSE/I, the "Authority") to identify and pursue opportunities to strengthen the evidence base, licensing, supply, cost-effectiveness and equitable adoption of medicines used outside of their original marketing authorisation.

The Programme is jointly sponsored by NHSE/I, the Department of Health and Social Care (DHSC), Medicines and Healthcare products Regulatory Agency (MHRA), National Institute for Health and Care Excellence (NICE), and National Institute for Health Research (NIHR).

Further details can be found at: https://www.england.nhs.uk/medicines-2/medicines-repurposing-programme/ The Medicines Repurposing Programme is inviting those interested organisations to express an interest to seek a major (type II) MHRA Marketing Authorisation variation for anastrozole.

The variation is to add a new indication to the current licence using published evidence.

The selected company (the "Bidder") would need to prepare a dossier for the MHRA, apply for the licence variation, and if granted update their licence, Summary of Product Characteristics and patient information leaflet with the new indication and related data, according to the regulatory review.

Interested organisations can access the PIN and register their interest here https://health-family.force.com/s/Welcome We will also be making time available for individual organisation discussions with NHSEI between 13th and 24th September 2021 should this be considered helpful.

Once registered, please contact liz.fleetwood1@nhs.net with your availability.

Deadline is 24th September @ 12:00noon

Key requirements

What the supplier must deliver

01

The selected company (the "Bidder") would need

The selected company (the "Bidder") would need to prepare a dossier for the MHRA, apply for the licence variation, and if granted update their licence, Summary of Product Characteristics and patient information leaflet with the new indication and related data, according to the regulatory review.

02

We will also be making time available

We will also be making time available for individual organisation discussions with NHSEI between 13th and 24th September 2021 should this be considered helpful.

Derived from the notice text — always confirm against the original documents.

Buyer intelligence

Make the case to bid

Reveal who to approach at NHS England, and generate a go-to-market strategy from their news, accounts and people.

Deep dive · beta

The full intelligence dossier

Our agent reads NHS England’s accounts, hunts live signals, finds the people who decide — and hands you a bid strategy plus a go-to-market influence plan, including what your team should post this week. You approve every paid step.

Source & provenance
OCID
5a66b02a-b3f6-4f9d-876e-e71c5cd285fe
Stage
preprocurement · Closed
Source
Contracts Finder
Buyer ref
CF-0339700D0O000000rwimUAA1
View the original notice on Contracts Finder

Contains public sector information licensed under the Open Government Licence v3.0. Source data © Crown copyright.

Market context

Who wins this kind of work

The suppliers and buyers around this opportunity — drawn from official award data. Drag to orbit; click a node to explore.

Top suppliers & buyers in Medical Equipment & Pharmaceuticals

Scroll to explore the market network

NHS England’s tender network

Assembling the network…